Basic/Clinical Science Session
Big Questions in Maintenance Dialysis
November 07, 2025 | 02:00 PM - 04:00 PM
Location: Room 342D, Convention Center
Session Description
Treatment advances often prompt new questions. This session reviews new treatments and approaches and discusses benefits and challenges in applying them to the care of patients receiving maintenance hemodialysis.
Learning Objective(s)
- Evaluate potential benefits and challenges of hemodiafiltration as a long-term kidney replacement therapy
- Explain the role of hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the management of anemia in dialysis-dependent kidney failure
- Discuss the state of evidence generation for SGLT2 inhibitors, GLP-1 receptor agonists, and potassium binders for patients with ESKD
- Assess how to move from generating evidence to implementing best practices in clinical care
Learning Pathway(s)
- Dialysis
- Hypertension and Cardiorenal Disorders
Moderators
Presentations
- Hemodiafiltration: Is It Time for Broad Adoption?
02:00 PM - 02:30 PM
- HIF-PHIs vs. Erythropoiesis-Stimulating Agents: When to Use Which?
02:30 PM - 03:00 PM
- SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Potassium Binders: Will They Become Part of ESKD Care?
03:00 PM - 03:30 PM
- How Do We Move from Generating Evidence to Implementing New Treatments in Clinical Care?
03:30 PM - 04:00 PM